NeuroTherapia is a company founded in 2015 to advance novel discoveries stemming from research by Drs. Mohamed Naguib and Joseph Foss. The company is focused on discovering and developing new chemical entities for the treatment of neuroinflammatory disease. The activation of immune cells, known as microglia, in the central nervous system (CNS) promotes an inflammatory response that serves as a hallmark for a range of neurologic disorders such as neuropathic pain, multiple sclerosis, traumatic brain injury, and Alzheimer’s Disease. Our lead product, NTRX-07, is a highly selective cannabinoid type 2 (CB2) receptor agonist with demonstrated central nervous system activity. The targeting of CB2 receptors on microglia by NTRX-07 significantly reduces the expression of inflammatory agents resulting in neuronal survival and proliferation.
 

NTRX-07 has been shown to improve memory loss observed in Alzheimer's Disease rodent models and represents a new approach to treating this challenging disease. 
Pre-clinical efficacy has also been established in multiple neuropathic pain models, including chemotherapy-induced peripheral neuropathy (CIPN), nerve ligation, and complex regional pain syndrome (CRPS) induced by ischemic injury.

​

NeuroTherapia completed first-in-man clinical safety studies in 2020. We are currently planning the next phase of clinical trials.

​

The work of NeuroTherapia has been generously supported by grants from the Alzheimer's Drug Discovery Foundation, the Alzheimer's Association and the Cleveland Clinic.